PRESS RELEASES

Nyxoah Announces Participation in the Stifel 2021 Virtual Healthcare Conference

adminComments Off on Nyxoah Announces Participation in the Stifel 2021 Virtual Healthcare Conference

Nyxoah Announces Participation in the Stifel 2021 Virtual Healthcare Conference

Mont-Saint-Guibert, Belgium. – November 3, 2021, 10:30 pm CET / 4:30 pm ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH)(“Nyxoah” or the “Company”), a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA), today announced that Olivier Taelman, Chief Executive Officer, will participate at the Stifel 2021 Virtual Healthcare Conference on Monday, November 15, 2021, with a virtual fireside chat at 4:00 pm CET/10:00 am ET.

A live webcast and replay of the fireside chat will be available on the Company’s investors relations website at https://investors.nyxoah.com/

About Nyxoah
Nyxoah is a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA). Nyxoah’s lead solution is the Genio® system, a patient-centered, leadless and battery-free hypoglossal neurostimulation therapy for OSA, the world’s most common sleep disordered breathing condition that is associated with increased mortality risk and cardiovascular comorbidities. Nyxoah is driven by the vision that OSA patients should enjoy restful nights and feel enabled to live their life to its fullest.

Following the successful completion of the BLAST OSA study, the Genio® system received its European CE Mark in 2019. Nyxoah completed two successful IPOs: on Euronext in September 2020 and NASDAQ in July 2021. Following the positive outcomes of the BETTER SLEEP study, Nyxoah received CE-Mark indication approval to treat Complete Concentric Collapse (CCC) patients, currently contraindicated in competitors’ therapy. Additionally, the Company is currently conducting the DREAM IDE pivotal study for FDA and US commercialization approval.

For more information, please visit http://www.nyxoah.com/

Caution – CE marked since 2019. Investigational device in the United States. Limited by U.S. federal law to investigational use in the United States.

Contacts:
Nyxoah
Jeremy Feffer, VP IR and Corporate Communications
jeremy.feffer@nyxoah.com
+1 917 749 1494

Gilmartin Group
Vivian Cervantes
IR@nyxoah.com

Attachment

admin

Related Articles
PRESS RELEASES

Webtel.mobi’s System and TUV Digital Currency – 21st Century Versions of Keynes’s International Clearing Union and Bancor

admin

WM’s independently reviewed system provides the fully-functional and globally operational structures and processes as proposed by John Maynard Keynes at the Bretton Woods Conference – and provide the key to reform the Global Financial System Webtel.mobi – Connecting the world WEBTEL.MOBI’s SYSTEM AND TUV DIGITAL CURRENCY – 21st CENTURY VERSIONS OF KEYNES’S INTERNATIONAL CLEARING UNION […]
PRESS RELEASES

Periscope by McKinsey Named a Leader in 2021 IDC MarketScape for B2B Price Optimization and Management Applications

admin

Customers get a comprehensive, customized pricing solution, including strategy, process, technology, change management, and training NEW YORK and LONDON, Oct. 05, 2021 (GLOBE NEWSWIRE) — McKinsey & Company today announced that Periscope by McKinsey, a suite of marketing and sales analytics solutions that helps companies achieve sustainable revenue growth, has been named a leader in […]
PRESS RELEASES

FALANA & FALANA Issues the Following Statement: Detention of a Wrong Person Nullifies Detention

admin

WASHINGTON, July 29, 2021 (GLOBE NEWSWIRE) — In its judgment of March 15, 2021 the Ecowas Court of Justice detailed the extensive violations of Cape Verdean law (along with international law) that occurred in the arrest and detention of Alex Saab. Consequently, the Court issued a binding unanimous decision in which it declared that Alex […]